Ketamine Presentation - PPT Revised
Ketamine Presentation - PPT Revised
Ketamine Presentation - PPT Revised
Ketamine History
First synthesized by the Belgian chemist C.L. Stevens in 1963, and patented by Parke Davis in 1966, Ketamine was approved by the FDA in February of 1970 It was first used on American Soldiers during the Vietnam War
Ketamine
Ketamine hydrochloride 2-(2- chlorophenyl)-2(methlamino)cyclohexanone hydrochloride
Structure of Ketamine
Ketamines dual anesthetic/hallucinogenic nature comes from it being a chiral compound, with its two enantiomers having different effects. S-Ketamine produces anesthetic effects while its enantiomer RKetamine produces the hallucinogenic effects.
Mechanism of Action
During normal nerve stimulation, the nerve impulse reaches the axon terminal, and Na+ and voltage dependent Ca+ gates are opened. The surge of free calcium into the axonal terminal acts as a messenger, and the contents are emptied by exocytosis into the synaptic cleft. The Ca+ is then quickly removed, and the neurotransmitter diffuses across the synaptic cleft and binds to specific protein receptors. A conformational change occurs and allows the ion channels to open and thus changing the membrane potential.
Mechanism of Action
Glutamate is used as an excitatory amino acid neurostramitter
Normally Acetylcholine enters to clear the neurotransmitter to allow for additional messages to be transmitted Ketamine is a nondepolarizing neuromuscular blocker, which inhibits and competes with acetylcholine from binding to its nicotinic receptor on the post synaptic membrane of the motor junction. Ketamines S-enantiomer (anesthetic effects) prevents the reuptake of Acetylcholine, thus allowing the receptor site to remain blocked
Mechanism of Action
Ketamine
Pain is detected by two different types of peripheral nociceptor neurons C-fiber nociceptors with slowly conducting unmyelinated axons
Ketamine
Ketamine has particularly been looked at in the Wind-Up Phenomena
rapidly repeated, identical noxious stimuli, which means that a simple touch input is converted into a painful sensation called allodynia. This can also mean that a pain stimuli can be magnified greatly and create a cascade of pain.
The wind up seems to be mediated by the NMDA receptors and can be reduced by Ketamine.
Palliative Care Antidepressants Alcohol and substance abuse clinics Reversing tolerance of morphine in cancer patients Treatment of stroke victims Alleviation of phantom pains Management of Complex Regional Pain Syndrome Neuro-protection
Benefits
Chronic pain can be maintained by a state of sensitization within the central nervous system that is mediated in part by the excitatory amino acids glutamate and asparate binding to the Nmethyl-D-asparate (NMDA) receptor Queens Researchers have found that in extremely small doses, opioid antagonists (ketamine), normally used to block the toxic effects of opioids- instead enhance pain-killing action in experimental models. The researchers discovered that for those who had already developed a tolerance to morphine, their tolerance was actually reduced with low doses of ketamine and pain was alleviated
Chronic Pain
Palliative Care
A small percentage of patients with far advanced diseases experience severe pain despite rapid upward titration of opioid analgesics, antiinflammatories, or other pain modulating drugs the use of low-dose ketamine in palliative care settings where opioid-refractory pain or opioidmedicated adverse effects prevent satisfactory pain relief Ketamine is known to be a potent NMDA receptor antagonist providing some rationale for its efficacy in treating neuropathic pain and enhancing opioid analgesia
Antidepressants
It is suggested that glutamate systems effect major depression and the mechanism in which the anti-depressants react in the body Clinical Neuroscience Research Unit
the first placebo-controlled, double-blinded trial to assess the treatment effects of single does of an NMDA receptor antagonist in patients with depression. seven subjects, was treated for two days with intravenous treatment with ketamine or saline solutions
Results
Subjects with depression evidenced significant improvement in depressive symptoms within 72 hours after ketamine but not with placebo infusion
Ketamine produces anti-craving properties because of the NMDA receptor and its influence on the similar ligandsacamprosate and ibogaine
Results
Savage and McCabe showed that LSDassisted psychotherapy had a positive effect on the outcome of treatment of heroin addicts: 25% treated with LSD remained abstinent from opiates for one year as opposed to only 5% of the control group remaining abstinent
Stroke Victims
Ketamine with its neuro-protective effect, mediated by antagonism of NMDA channels located on central neurons. Such antagonism ultimately prevents calcium influx during states of neuro-cellular ischemia.
Phantom pain
This pain is due to the hyperactivity of NMDA receptors. Ketamine is administered to block the receptor sites and alleviate the pain Those who received the ketamine infusion the stump pain was alleviated for 31 hours and were treated 4 times a day and showed no tolerance. The saline group still complained of phantom pain
Results
Alleviating all the pain was felt by 25 patients (76%) Partially eliminating the pain of 6 patients (18%) No relief was felt by 2 patients (6%) Although the relief was not indefinite, 54% said that the pain was alleviated for 3-4 months with one treatment After two treatments, 33% of the patients stated the pain was alleviated for more than 3 years!!
Ketamine
Effects of this drug are mediated by N-methylD-asparate (NMDA) receptors, opoid and muscaranic receptors. Ketamine is a anesthetic and hallucinogenic.
Ketamine
Despite the side effects of Near Death Experiences, Ketamine has proved to be very beneficial and useful in the medical field both animal and human Ketamine in the future will continue to provide aid with disease pain and maybe even life time cures of certain ailments